 |
|
|
| |
News
FOR MEDIA
Argos Therapeutics, Inc. is developing breakthrough immunotherapies
that target unique features of a patient’s disease. This new generation
of personalized therapeutics trains the immune system to recognize and
attack diseases. Argos’ scientific leadership in RNA-loaded dendritic
cells and advanced manufacturing processes provide a platform to tackle
virtually all forms of cancers and infectious diseases.
View a company backgrounder for more detailed information on Argos Therapeutics’ business
and approach.
LATEST NEWS & PRESS RELEASES
2008
Argos Therapeutics Secures $35.2 Million Series C Financing
—Funding to Advance Arcelis™ Personalized Immunotherapy Programs in HIV and Cancer,
and Novel Immunosuppressant, CD83—
Click for the full story
Argos Therapeutics Presents Positive Phase 1 Safety Data for its Arcelis™ Platform in HIV at Keystone Symposia
Click for the full story
Argos Therapeutics Presents Data on the Mechanism of Immunosuppression by Soluble CD83 at the Canadian Society of Transplantation Congress
Click for the full story
Argos Therapeutics Publishes Novel Approach to Amplifying HIV Genes for Personalized Immunotherapy Treatments for HIV
Click for the full story
2007
Argos Therapeutics and Therakos, Inc. Enter Exclusive Agreement for Regulatory T Cell Technology
Click for the full story
Argos Therapeutics Presents Positive Data on its Personalized Cancer Immunotherapy Programs at ISTBC Meeting
Click for the full story
Argos Therapeutics featured in Fierce Biotech
Click for the full story
Argos Therapeutics’ Scientific Founder Ralph Steinman, M.D., Receives Lasker Award for Basic Medical Research
Click for the full story
Argos Therapeutics Presents Immunosuppression Data for Soluble
CD83 at the American Society of Transplantation Congress 2007
Click for the full story
Argos Therapeutics Raises $5.0 Million in Debt Financing
Click for the full story
Argos Therapeutics Awarded U.S. Patent for CD83
Protein for Use in Immunological Disorders
Click for the full story
Personalized Immunotherapy Clinical Trial Initiated
in HIV Patients with Argos Therapeutics´ AGS-004
Click for the full story
B-Cell Chronic Lymphocytic Leukemia Clinical Trial
Initiated with Argos Therapeutics´ AGS-005 Personalized Immunotherapy
Click for the full story
2006
Argos Therapeutics Appoints Dr. John Bonfiglio
Chief Executive Officer
Click for the full story
Argos Therapeutics Awarded NIH Contract to Further
Develop HIV Immunotherapy Candidates — $21 Million Contract for Novel
Immunotherapies
Click for the full story
Argos Therapeutics Initiates Phase I/II Trial with
AGS-003 Personalized Immunotherapy in Advanced Kidney Cancer
Click for the full story
Argos, Beckman Coulter Sign License Agreement: CD83 Licensure to
Advance Work on Autoimmune Disorders, Transplant Rejection Therapy
Click
for the full story
2005
Argos Therapeutics and DC Bio Corp. Announce New Clinical Trial to Begin
for Chronic Lymphocytic Leukemia Using Argos´ Personalized Dendritic
Cell Vaccine
Click
for the full story
Argos Therapeutics and Novo Nordisk Announce Agreement
to Develop Treatment for Systemic Autoimmune Disorders
Click for
the full story
Argos Therapeutics Data From Kidney Cancer Vaccine Phase
I/II Study To Be Presented At Two Upcoming Oncology Conferences
Click
for the full story
Argos Therapeutics Receives $1.0 Million Grant for Lupus
Research
Click
for the full story
2004
Merix Bioscience Changes its Name to Argos Therapeutics
Click
for the full story
Merix Bioscience Announces New Leadership and Board Members
Click
for the full story
Merix and Kirin to Develop Personalized Dendritic Cell
Vaccines for Cancer, HIV and Other Diseases
Click
for the full story
Merix Bioscience Launches Trial for New Kidney Cancer
Vaccine
Click
for the full story
2001
Merix Bioscience Announces Agreement with Geron Corporation for Development
of Cancer Vaccines
Click
for the full story
Merix Bioscience Licensed Patent to Use RNA Loaded Cells
to Treat Cancers and Pathogen Infections
Click
for the full story
Merix Bioscience Appoints World's Leading Dendritic Cell
Researchers to Expert Advisory Committee
Click
for the full story
Merix Bioscience Establishes European Subsidiary
Click
for the full story
Merix Bioscience Completes $39.5 Million Private Financing
Click
for the full story
|
|
 |
|
